Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT202 in metastatic or recurrent gynecological tumors
NCT05238818Phase 1Unknown
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GT202 in Cervical Cancer (CC), ovarian cancer and endometrial cancer (EC). Primary endpoints: Dose-limiting toxicity at 28 days, Adverse Events at 2 years and 1 more. Status: unknown.
02
Drugs
GT202
03
Conditions
Cervical Cancer (CC)ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT05238818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238818.